Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (DE:3G0)
FRANKFURT:3G0
Holding DE:3G0?
Track your performance easily
3G0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.02 - €13.70
Previous Close€7.75
Volume0.00
Average Volume (3M)1.40K
Market Cap
€562.57M
Enterprise Value€429.86M
Total Cash (Recent Filing)$139.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Mar 27, 2025EPS Estimate
-€0.32Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding71,124,625
10 Day Avg. Volume290
30 Day Avg. Volume1,402
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.12
Price to Sales (P/S)11284.20
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.27K
Enterprise Value/Gross Profit1.01K
Enterprise Value/Ebitda-4.28
Forecast
1Y Price Target
€21.23Price Target Upside174.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Altimmune News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAltimmune announced completion of an end-of-Phase 2 meeting with FDA, attaining agreement on the design of a Phase 3 registrational program for pemvidutide in obesity that is expected to include four Phase 3 trials, VELOCITY-1, -2, -3, and -4.
Market PotentialAltimmune plans to submit IND applications for pemvidutide in up to three additional indications, potentially expanding to more patient populations.
Safety And EfficacyThe FDA confirmed there were no safety signals for pemvidutide, allowing the focus to be on its key efficacy attributes such as weight loss and lipid reduction.
Bears Say
Clinical TrialsHepTcell Ph. II trial discontinuation making pemvi the core value-driver.
Drug DevelopmentSurvodutide data show one of the worst tolerability profiles for a GLP-based candidate.
Product PipelineThe company is discontinuing development of hepatitis B candidate HepTCell which we considered upside, and thus has no impact on our valuation.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.83% Insiders
11.76% Mutual Funds
9.81% Other Institutional Investors
63.90% Public Companies and
Individual Investors
3G0 FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was €5.02 and its highest was €13.70 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Nov 12, 2024. The company reported -€0.305 earnings per share for the quarter, beating the consensus estimate of -€0.34 by €0.035.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of €831.275 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -€0.32.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 71,124,626 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -€0.305 in its last earnings report, beating expectations of -€0.34. Following the earnings report the stock price went up 24.779%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Farallon Capital Management, L.L.C.. It holds Altimmune Inc’s shares valued at 169K.
---
Altimmune Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.23 (174.07% Upside)
€21.23 (174.07% Upside)
Blogger Sentiment
Bullish
DE:3G0 Sentiment 98%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.38%
12-Months-Change
Fundamentals
Return on Equity
-72.96%
Trailing 12-Months
Asset Growth
-11.23%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
3G0 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of pemvidutide, including successful trial enrollments and FDA alignment on Phase III plans. However, financial challenges such as increased net loss and decreased cash reserves were noted. Overall, the sentiment leans positive due to the strategic advancements and strong cash position to support future developments.Read More>---
3G0 Stock 12 Month Forecast
Average Price Target
€21.23
▲(174.07% Upside)
Technical Analysis
Best Analysts Covering 3G0
1 Year
1 Year Success Rate
18/35 ratings generated profit
1 Year Average Return
+11.92%
reiterated a buy rating 2 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 51.43% of your transactions generating a profit, with an average return of +11.92% per trade.
---